Bacteriuria Clinical Trial
Official title:
Reduction of Bacteriuria in Subjects Practicing Intermittent Catheterization
NCT number | NCT01143116 |
Other study ID # | YA-ABC-0003 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | November 2010 |
Est. completion date | May 2011 |
Verified date | May 2022 |
Source | Wellspect HealthCare |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main objective is to investigate two types of antibacterial catheters regarding their antibacterial efficacy. The study will investigate if silver added to the coating of a urinary catheter exerts antibacterial activity that will have an impact on bacteria quantity in the urine bladder among users of intermittent catheterization.
Status | Completed |
Enrollment | 20 |
Est. completion date | May 2011 |
Est. primary completion date | May 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Provision of informed consent - Female/male aged 18 years and over - Practicing intermittent catheterization at least 4 times daily for at least 6 weeks - A minimum of 104 CFU of bacteriuria Exclusion Criteria: - Ongoing, symptomatic UTI at enrollment - Known urethral stricture - Basic tumorous disease - Previous prostate surgery - Subjects known to be immunocompromised e.g. HIV or diabetes - Treatment with antibiotics and/or intravesical antiseptics for the past 30 days before study start - Involvement in the planning and conduct of the study (applies to both Astra Tech staff or staff at the study site) - Pregnancy or breast feeding - Previous enrolment or randomisation of treatment in the present study - Participation in a clinical study that possibly might interfere with the present study, as deemed by the investigator - Severe non-compliance to protocol as judged by the investigator and/or Astra Tech |
Country | Name | City | State |
---|---|---|---|
United Kingdom | The Robert Jones and Agnes Hunt Orthopaedic and District Hospital NHS Trust | Oswestry | Shropshire |
Lead Sponsor | Collaborator |
---|---|
Wellspect HealthCare |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total Bacteria Count Change From Baseline and After 24 Hours. | Change from baseline (urine sample immediately before first catheterization with study product) and after 24 hours of intermittent catheterization with the randomised study catheter. | Baseline and after 24 hours | |
Primary | Total Bacteria Count Change From Baseline and After 48 Hours. | Change from baseline (urine sample immediately before first catheterization with study product) and after 48 hours of intermittent catheterization.
After the baseline sample the subject had 24 hours with study randomized catheter and then changed to 24 hours on non-study sterile intermittent catheterization. |
Baseline and after 48 hours | |
Primary | Total Bacteria Count Change From Baseline and After 7-14 Days. | Change from baseline and after 7-14 days. Change from baseline (urine sample immediately before first catheterization with study product) to after 7-14 days. | Baseline and after 7-14 days | |
Secondary | Escherichia Coli Mean Bacteria Count Change From Baseline to 12 Hours | Escherichia coli mean bacteria count change from baseline (subjects with positive values) to after 12 hours.
Baseline (urine sample immediately before first catheterization with study product) and then at 12 hours of study catheter use. |
After first catheterization with study product and after 12 hours | |
Secondary | Escherichia Coli Mean Bacteria Count Change From Baseline to 24 Hours | Escherichia coli mean bacteria count change from baseline (subjects with positive values).
Baseline (urine sample immediately before first catheterization with study product) and then at 24 hours of study catheter use. |
After first catheterization with study product and after 24 hours | |
Secondary | Enterococcus Faecalis Mean Bacteria Count Change From Baseline to 12 Hours | Enterococcus faecalis mean bacteria count change from baseline (subjects with positive values).
Baseline (urine sample immediately before first catheterization with study product) and then at 12 hours of study catheter use. |
After first catheterization with study product and after 12 hours | |
Secondary | Enterococcus Faecalis Mean Bacteria Count Change From Baseline to 24 Hours | Enterococcus faecalis mean bacteria count change from baseline (subjects with positive values).
Baseline (urine sample immediately before first catheterization with study product) and then at 24 hours of study catheter use. |
After first catheterization with study product and after 24 hours | |
Secondary | Urine Silver Concentration Change From Baseline to 24 Hours | Urine silver concentration change from baseline excluding five subjects with extreme outlier values at baseline due to laboratory error during analysis and all subjects presented normal values during study follow up.
Samples for analysis of silver concentration in urine were collected at baseline, after last catheterization with investigational product (at the very end of day 2) at the last catheterization at day 3 and at study termination (at 7-14 days). |
Baseline to 24 hours | |
Secondary | Urine Silver Concentration Change From Baseline and After 48 Hours | Urine silver concentration change from baseline excluding five subjects with extreme outlier values at baseline due to laboratory error during analysis and all subjects presented normal values during study follow up.
Samples for analysis of silver concentration in urine were collected at baseline, after last catheterization with investigational product (at the very end of day 2) at the last catheterization at day 3 and at study termination (at 7-14 days). |
After first catheterization with study product and after 48 hours | |
Secondary | Urine Silver Concentration Change From Baseline to 7-14 Days | Urine silver concentration change from baseline excluding five subjects with extreme outlier values at baseline due to laboratory error during analysis and all subjects presented normal values during study follow up.
Samples for analysis of silver concentration in urine were collected at baseline, after last catheterization with investigational product (at the very end of day 2) at the last catheterization at day 3 and at study termination (at 7-14 days). |
At baseline and after 7-14 days | |
Secondary | Blood Silver Concentration Change From Baseline and After 24 Hours | Samples for analysis of silver concentration in blood were collected at baseline, after last catheterization with investigational product (at the very end of day 2) at the last catheterization at day 3 and at study termination (at 7-14 days). | After first catheterization with study product and after 24 hours | |
Secondary | Blood Silver Concentration Change From Baseline and After 48 Hours | Samples for analysis of silver concentration in blood were collected at baseline, after last catheterization with investigational product (at the very end of day 2) at the last catheterization at day 3 and at study termination (at 7-14 days). | After first catheterization with study product and after 48 hours | |
Secondary | Blood Silver Concentration Change From Baseline and After 7-14 Days | Samples for analysis of silver concentration in blood were collected at baseline, after last catheterization with investigational product (at the very end of day 2) at the last catheterization at day 3 and at study termination (at 7-14 days). | After first catheterization with study product and after 7-14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03131609 -
Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department
|
||
Withdrawn |
NCT04230746 -
Effect of Antibiotics on Urinary Microbiome
|
Early Phase 1 | |
Enrolling by invitation |
NCT01349738 -
Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants
|
N/A | |
Completed |
NCT02922868 -
Assessment of Infection Control, Practice Efficiency, and Health Economics of Sheathed Versus Standard Cystoscopy
|
N/A | |
Withdrawn |
NCT02052674 -
Retained Urine Volume and Bacteriuria in Traditional Versus Vented Urine Drainage Systems
|
Phase 1 | |
Completed |
NCT00258089 -
A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections
|
Phase 3 | |
Recruiting |
NCT04985110 -
Administration of Antibiotic Prophylaxis for Transperineal Prostate Biopsy in Cipto Mangunkusumo Hospital
|
Phase 2 | |
Recruiting |
NCT02032394 -
Effect of Chlorhexidine on Bacteriuria
|
Phase 4 | |
Withdrawn |
NCT03816384 -
Effect of Active Drain Line Clearance on Catheter-Associated Bacteriuria
|
N/A | |
Enrolling by invitation |
NCT00717600 -
Bacteriuria Eradication Through Probiotics
|
Phase 1 | |
Completed |
NCT00126698 -
Prophylactic Antibiotics on Urethral Catheter Withdrawal
|
Phase 4 | |
Completed |
NCT00258102 -
A Study of the Safety and Effectiveness of Levofloxacin Compared With Lomefloxacin in the Treatment of Complicated Urinary Tract Infections
|
Phase 3 | |
Completed |
NCT02797613 -
Restricted Reporting for Positive Urine Cultures
|
N/A | |
Not yet recruiting |
NCT04658719 -
A Pilot Study To Assess The Impact Of A Camstent Coated Catheter On Clinical Bacteriuria
|
N/A | |
Completed |
NCT02575495 -
A Randomized Control Trial of Antibiotic Treatment Duration For Asymptomatic Bacteriuria After Kidney Transplantation
|
Phase 2 | |
Completed |
NCT02277171 -
Evaluation of Safety and Tolerability of Nitric Oxide Impregnated Urinary Catheters
|
Phase 1 | |
Completed |
NCT01033383 -
Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents
|
Phase 1 | |
Completed |
NCT00093938 -
Cranberry Juice for Preventing Bacteria in Urine During Pregnancy
|
Phase 1 | |
Completed |
NCT01691430 -
A Trial of Cranberry Capsules for Urinary Tract Infection Prevention in Nursing Home Residents
|
Phase 3 | |
Completed |
NCT01114347 -
Prevention of Nosocomial E. Coli Infections After Placement of an Indwelling Catheter During Pelvic Surgery: an Evaluation of Cranberry Gel Capsules
|
Phase 2 |